LIHT CANNABIS Forum: Community User: moojoo

Aber wie kommst du darauf, dass Du gemeint warst, fühlst Du dich etwa angesprochen? Ich hatte, im Gegensatz zu Dir, keinen Namen erwähnt, dass wäre ja auch Strafrechtlich verfolgbar;-))))

@Pipjoe: Vergleich erstmal diese Kommentare mit deinen eigenen... Ich sage nur: Wer im Glashaus sitzt... ;)

'Kleiner Pflegefall' lässt sich zivilrechtlich gut verwerten, rechtsfreier Raum existiert nicht, solch Kommentare haben auch nichts mit Meinungsfreiheit zu tun. Haschiboy, c u soon, c u soon. Everybody here seems to be frustrated... hängt ganz klar mit Mara zusammen bzw den Verlusten, tztz.

Tja, JaxOtte, der kleine Plegefall im Forum ist Resistent gegen alles der müllt uns seit Wochen voll, im Veritas Forum hatte Er ja schon mit Beleidigungsklagen gedroht, wir müssen wohl weiter mit dem Mist leben, schade ;-((

Wann ist den wieder ein wichtiger kursrelevanter Termin?

Jeder, der hier tatsächlich interessiert ist, hat die news wohl selbst abonniert. Wieso werden die hier ständig gespamt?

Pipi Kopp.. Halt dein Finger von der Tastatur weg... Nervst

Pipi so what? With Selling in Minus i will Not getting rich ;)

Verluste soweit das Auge reicht. But: listen to pipjoe and get rich.

Dann bist du einer der glücklichen. Die wenigsten werden hier einen tieferen Ek als den jetzigen Kurs haben. Wie auch..

Nö...

Super Empfehlung. Die meisten sind hier garantiert im Minus.

Danke pipjoe, guter Artikel, stark recherchiert. Viel Gerede, wenig Konkretes, Mara sollte sich fokussieren und nicht an 3, 4 Fronten gleichzeitig versuchen präsent zu sein. Meine Empfehlung: Sell.

Was bedeutet das jetzt?

:-)

Sorry Tito & friehds, war nicht der aktuellste, aber ihr kennt mich, bin ein Teamplayer, hier, bitte sehr Marapharm Ventures Inc. Announces The Close Of A Tranche Of A Non-Brokered Private Placement Unit Offering Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) (“Marapharm” or the “Company”) announces the close of the first tranche of the non-brokered private placement (the “Unit Offering”) of up to 3,000,000 units (“Units”) at CDN $0.865 per Unit to raise gross proceeds of up to $2,595,000. The first tranche closed today with proceeds totaling $1,339,680. from the sale of 1,548,760 units. Marapharm intends to close the final tranche no later than March 30, 2018. The Unit will consist of one common share and one common share purchase warrant. Each whole common share purchase warrant (“Purchase Warrants”) will entitle the holder to acquire one common share at $0.87. The Purchase Warrants may be exercised at any time until one year from the closing of the Unit Offering. The net proceeds raised from the Unit Offering are intended to be used for (i) further development of the Company’s Las Vegas project (ii) further development of the Company’s project in Washington State (iii) and general corporate purposes. Marapharm will pay cash finder fees of 10% of the gross proceeds raised from subscriptions in the Unit Offering from persons introduced to the Company by certain eligible Finders. Marapharm will also issue non-transferable common share purchase warrants (“Finder’s Warrants”) equal to 10% of the number of Units subscribed for by persons introduced to the Company by eligible Finders. Each Finder’s Warrant will allow the Finder to purchase one additional common share at $0.87 for a period of 14 months from the closing of the Unit Offering.   ABOUT MARAPHARM VENTURES INC. Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.   FOR FURTHER INFORMATION: www.marapharm.com or Linda Sampson, CEO 778-583-4476 email info@marapharm.com   SOCIAL MEDIA: Facebook: facebook.com/marapharm Twitter: twitter.com/marapharm Web Program: marapharm.tv   STOCK EXCHANGES: Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, and in Europe, ticker symbol 2M0 on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin. Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.   MARIJUANA INDUSTRY INVOLVEMENT: Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate. Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm’s ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm’s business is conducted in a manner consistent with state law and is in compliance with licensing requirements. Copies of licenses are posted on Marapharm’s website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.   FORWARD – LOOKING STATEMENTS: Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward- looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward- looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.